XML 99 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Acquisitions (Schedule of Unaudited Pro Forma Information) (Details) (Cadence Pharmaceuticals, Inc., Specialty Pharmaceuticals, USD $)
In Millions, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Mar. 28, 2014
Mar. 29, 2013
Mar. 28, 2014
Mar. 29, 2013
Cadence Pharmaceuticals, Inc. | Specialty Pharmaceuticals
       
Business Acquisition, Pro Forma Information [Line Items]        
Net sales, pro forma $ 588.2 $ 608.9 $ 1,163.7 $ 1,130.1
Net (loss) income, pro forma $ (18.4) $ 4.4 $ (2.6) $ (35.7)
Basic (loss) earnings per share, pro forma (in usd per share) $ (0.32) $ 0.08 $ (0.04) $ (0.62)
Diluted (loss) earnings per share, pro forma (in usd per share) $ (0.31) $ 0.08 $ (0.04) $ (0.62)